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Introduction
Scientists and clinicians need to know
the authorship, author interests, and
origination of the articles they read to
judge them appropriately. Since 1985, the
International Committee of Medical Jour-
nal Editors (ICMJE) has provided evolving
guidance on how authorship should be
managed in the complex setting of modern
biomedical science [1,2], to the benefit of
the published literature. Issues such as
accountability, fraud, conflicts of interest,
trial registration, and access to data have
been considered by this voluntary, self-
funded, closed-membership group of select
general medical journal editors (http://
www.icmje.org/) [3–5]. However, certain
industry practices, including publications
planning, ghostwriting, and guest author-
ship, have yet to be adequately addressed.
On the basis of industry publications and
documents, textual analysis, and direct
working experience in the ‘‘medical com-
munications’’ sector, I show here how
pharma has succeeded not merely in
outmaneuvering the ICMJE guidelines,
but is able to use them as the basis for
inappropriate attributions of authorship.
Commercial Origination
Industry trials and publications have
scientific but also commercial functions. In
its dealings with academia, industry takes
the misguided view that it should exag-
gerate the former and conceal the latter.
Effective publications planning based on
this premise enables industry to exert
substantial control over the literature on
its products and configure understandings
of medicine such that their use seems
reasonable [6–10]. Industry has realized
that origination is a key determinant of
how publications are perceived, and one
that current guidelines do not adequately
address. Accordingly, while collaboration
between industry and academia can have
benefits, academic authors groomed as
‘‘key opinion leaders’’ (KOLs) [6,11] may
be used not only to endorse publications,
but also to convey the impression the
publications were originated by academ-
ics. ‘‘Medical communications’’ agencies
bear joint responsibility for these practices,
and for the systematic masking of corpo-
rate origination within the medical litera-
ture. Industry claims its activities are
ethical, but this is disingenuous and rests
on two subtle strategies: first, the use of
weak definitions or convenient under-
standings of concepts such as accountabil-
ity, responsibility, authority, intellectual
contribution, contributorship, guest au-
thorship, and ghostwriting; and second,
the exploitation of flaws in current guide-




The important distinction between au-
thorship and contributorship proves espe-
cially helpful to industry. Although con-
tributorship was proposed as a replacement
for authorship [12,13], contributorship
listings have acquired unintended parallels
with advertising small print, and accord-
ingly are used by industry to reduce its own
visibility—despite, ironically, being used as
the basis of claims to transparency.
Through the exploitation of contributor-
ship, crude ghostwriting and guest author-
ship are being replaced by more subtle
exaggeration or understatement of autho-
rial contributions. This practice is difficult
to trace, since it involves subjective judg-
ments, and the parties involved—compa-
nies, writers, and KOLs —all have incen-
tives to allow their true levels of
contribution to be aggrandized or down-
played. These practices gain succor from
weak definitions of ghostwriting and ghost
authorship, which the World Association of
Medical Editors (WAME) and Council of
Science Editors (CSE) deem not to have
occurred if a writer is ‘‘mentioned in the
manuscript’’ (WAME) or receives an ‘‘ap-
propriate’’ place ‘‘in the author byline or
Acknowledgments’’ (CSE) [14,15]. Indus-
try and medical writers’ organizations are
thus able publicly to condemn ghostwriting
using comparable framings [16–18], while
the misattribution of authorship remains
widespread.
From industry’s perspective, the most
useful feature of the current ICMJE guide-
lines is the formula used to distinguish
between authors and contributors (Figure 1).
To qualify as an author, an individual must
(1) contribute substantially to either concep-
tion and design, or acquisition of data, or
analysis and interpretation of data; and (2)
draft the article or revise it critically for
important intellectual content; and (3) be
responsible for final approval of the manu-
script [2]. This ‘‘triple-lock’’ formula has
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tion. Provided academics make some con-
tribution to design or data analysis, some
revisions to a manuscript, and approve it,
they are required to be named as authors. By
contrast, industry may conduct most of the
design, data collection and analysis, and all
the writing, but if sign-off is ceded to the
academic, it is disqualified from authorship.
Unsurprisingly, the practice of ceding final
sign-off to academic ‘‘authors’’ is widespread
in commercially driven publications.
Further Hazards of the
‘‘Triple-Lock’’
The ‘‘triple-lock’’ formula also helps
downplay the importance of planning and
writing texts. Only in clause 2 is ‘‘drafting’’
acknowledged as a component of author-
ship, but since this clause can be satisfied
by revision, it enables the planner and
writer to be excluded. In reality, drafting
constitutes a substantial intellectual contri-
bution to the form and content of
manuscripts. It is for this reason that
industry seeks to control it, while evading
the visibility of byline authorship. The
Summary Points
N Academic authorship boosts the credibility of industry publications and masks
their commercial function.
N Alongside traditional ‘‘guest authorship’’ and ghostwriting, industry may simply
exaggerate the contribution of named academic authors and downplay that of
commercial writers, who are excluded from authorship but listed as
contributors in the small print.
N Rather than obstructing industry, the current International Committee of
Medical Journal Editors (ICMJE) authorship guidelines provide a ready tool for
misattributing authorship. Industry also relies on selective interpretations of key
authorship concepts.
N The ICMJE guidelines should be fundamentally revised and the concept of
origination given comparable importance to authorship and contributorship.
N Companies and writers who work on industry publications should be listed as
byline authors.
Figure 1. The ICMJE ‘‘triple lock’’ formula is a tool for industry. If final sign-off is ceded to the academic ‘‘author’’, industry is disqualified from
authorship even if it is responsible for most of the study and manuscript development. Manuscript writers are also disbarred even if they have sign-
off, unless they were involved in other aspects of the study. These features give industry the opportunity to conceal its originating role behind the
names of academic collaborators. Industry also carries out further originating activities not catered for in the ICMJE formula (shown in brackets). The
percentage contributions shown here are for illustrative purposes only, and in reality vary widely.
doi:10.1371/journal.pmed.1001072.g001
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these linked objectives.
Industry finds further justification for
self-concealment behind KOL ‘‘author-
ship’’ in the ICMJE requirement that
authors should ‘‘take responsibility for
appropriate portions of the content’’ of
publications [2]. This statement and the
‘‘triple lock’’ are both attempts to imple-
ment the connecting concepts of account-
ability, responsibility, and guarantorship
[5,12,19]. One difficulty with the current
ICMJE wording on ‘‘responsibility’’ is
that it emphasizes ‘‘content’’ alone, rather
than all aspects of the publication.
Furthermore, ‘‘content’’ can be narrowly
interpreted by industry to omit the
framings, nuanced constructions, and
selectivity of data that are crucial to drug
marketing [6,9]. Moreover, ‘‘responsibil-
ity’’ and ‘‘accountability’’ are readily
conflated by industry with notions of
authority and expertise, such that it
becomes legitimate for KOLs to assume
responsibility for texts they neither orig-
inated nor wrote, while the contributions
of the true originators are downplayed on
the grounds that they lack the ‘‘authority’’
to stand for them. Writers and companies
with the ability to generate academic texts
should not be permitted to step back from
responsibility on such disingenuous
grounds; indeed, the true ‘‘authority’’
behind industry publications belongs to
corporations, not their academic collabo-
rators. Ultimately, industry’s KOL-fo-
cused construction of ‘‘authority’’ is
designed once again to downplay its
own role—but also to appeal to the vanity
of KOLs. Sadly, it is a construction that
finds a ready reception within the culture
of contemporary medicine.
Further aspects of current authorship
practices provide support for industry.
Notably, the ICMJE guidelines place great
emphasis on the contributions of named
individuals. This approach reflects tradi-
tional authorship customs, but assists
unethical practices in two respects. Firstly,
it helps entities, and in particular compa-
nies, remain concealed, particularly if their
authorial role involves many individuals,
each of whom is only a minor contributor
to the finished publication. Secondly, it
gives insufficient exposure to the process of
origination by which publications are
conceived and come into being—for
commercially driven articles that exist to
promote specific products, this informa-
tion is vital to the reader.
Moreover, another deficiency in the
current ICMJE guidelines concerns their
policy on author access to data [5]. There
is no requirement that any authors have
permanent access to the study data or the
right to re-analyze the data as they
choose. Rather, authors need only have
had access to the trial data at the time the
study was conducted and the publication
prepared. This is a weak position for the
guidelines to adopt, whereas pharma, by
contrast, asserts company ownership of
the data in the trials ‘‘authored’’ by its
KOLs [20].
In sum, the current ICMJE guidelines
provide pharmaceutical and medical
communications companies with the op-
portunity to sequester their contributions
in the small print of publications, despite
bearing responsibility for conception,
design, and analysis of many studies,
retaining control of databases, and fre-
quently writing manuscripts, scheduling
publications, and selecting journals.
KOLs whose contributions may be mod-
est and who lack full permanent access to
the data may be the only individuals who
qualify for authorship under ICMJE
criteria. The current guidelines are there-
fore not an obstacle but a vehicle through
which origination and authorship can be
misrepresented to readers in the services
of marketing, while enabling the compa-




For 26 years the ICMJE authorship
guidelines have evolved by periodic adap-
tation, and in their current form have
achieved broad support, notably from
industry and commercial writers [20–23].
Clearly, however, a fundamental review is
required. Indeed, such is the importance
of the guidelines that the process by which
they are devised and updated should itself
be reviewed. In the meantime, guidelines
developed by organizations involved with
industry publications [21,22] should not
be recommended by journals to prospec-
tive authors. Furthermore, the commer-
cially implanted phrase ‘‘industry-spon-
sored’’ trials (and publications), which is
itself designed to downplay industry’s role,
should be replaced in the language of
journals and medicine by the more
truthful phrase ‘‘industry trials.’’
With respect to the authorship issues
discussed in this article, several philosoph-
ical clarifications are necessary. Firstly,
while the categories of authorship, con-
tributorship, and guarantorship remain
important, comparable emphasis should
be placed on the concept of origination,
which differs from these categories in that
it refers to a process rather than individual
people. Some journals and indeed industry
guidelines have made steps in this direc-
tion [24,25], but these are insufficient.
Crucial aspects of origination should be
given immediate visibility: for instance, as
depicted in Figure 2, companies and
medical writers should be included among
the named authors whenever appropriate,
and both companies and specific drugs
supported by the publication should be
listed immediately below the author by-
line. This would enable readers immedi-
ately to recognize publications’ commer-
cial, as well as scientific, functions
(Figure 2).
Secondly, it should be explicitly ac-
knowledged that planning, drafting, and
writing generally constitutes a significant
intellectual contribution to a publication,
and in most cases should require the
individual and/or entity responsible to be
listed as a byline author. This position has
previously been advocated by Gøtzsche
[23] and is implicit in statements by
WAME and the policies of some journals
[25–27]. Receiving input or ‘‘direction’’
from KOLs should not disbar writers from
authorship. It should be emphasized that
whenever writers are omitted from byline
authorship by underplaying their true
contribution, this constitutes ghostwriting,
including when writers are listed as
contributors.
Thirdly, greater provision should be
made for authorship by entities, and in
particular companies. Whenever an entity
carries out activities that in the case of an
individual would justify authorship, it
should be listed as a byline author.
Fourthly, it should be clarified that
responsibility and accountability pertain
to all aspects of manuscripts, and all
individuals and entities involved in devel-
oping them must be accountable. Respon-
sibility for ‘‘content’’ should not be ceded
to academic authors alone if others helped
plan, write, or revise the manuscript.
Academics may remain the only authors
with the expertise to guarantee some
aspects of content, but other key origina-
tors must also take visible responsibility
(and credit) as byline authors.
In keeping with these principles, several
specific measures should be considered:
1. With respect to the ICMJE guidelines,
the ‘‘triple-lock’’ formula for distin-
guishing authors from contributors
should be discarded. A model in which
a variety of contributions require an
individual or entity to be listed as an
author should replace it.
2. For submissions in which companies
or similar entities played any role in
PLoS Medicine | www.plosmedicine.org 3 August 2011 | Volume 8 | Issue 8 | e1001072finance, planning, or development, a
separate schedule (or supplement to
the competing interests statement)
should be completedt oi d e n t i f ys a -
lient features of origination, including
who planned and wrote the piece,
which specific products the publica-
tion supported, and how it was
financed. To ensure completeness, a
company lawyer should be required
to sign off. A further option would be
to treat the agreement to publish as a
legal contract, with accurate comple-
tion of the schedule a contractual
condition.
3. Companies should be encouraged to
provide full, permanent data access to
academic authors. In all cases in which
a company retained control or owner-
ship of a trial database, the company
itself should be required to be listed as
one of the first three (and therefore
cited) byline authors.
Finally, journal publishers and groups
such as the ICMJE, CSE, and WAME
should seek to establish links with bodies
responsible for other aspects of medical-
scientific discourse, such as continuing
medical education (CME) organizations,
professional societies, Web sites, and
congresses, with a view to establishing an
integrated, international standard of trans-
parency in science [6]. Such a standard
should require truthful, prominent display
of salient origination and authorship.
Academics would be able to place greater
trust in articles, presentations, and CME
courses bearing the standard’s logo, and
exercise appropriate caution with those
which did not.
The ICMJE guidelines will always be a
work in progress, but the adjustments
proposed here have the potential to end
the self-concealment and authorial mis-
representations that mar industry’s contri-
butions to the literature. Furthermore,
they have the potential to help industry
achieve the enhanced respect its beneficial
contributions to medicine deserve. Indus-
try publications will always have a com-
mercial valence alongside their scientific
and medical content: this should hence-
forth be truthfully displayed, and no
longer downplayed or concealed.
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